Imugene Limited (AU:IMU) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Imugene Limited, a company specializing in immuno-oncology, has scheduled an investor webinar to discuss recent Phase 1b clinical trial results for their blood cancer treatment, azer-cel. The webinar, featuring CEO Leslie Chong and CMO Dr. Paul Woodard, aims to update stakeholders on the progress and potential of the trial. Interested parties can join the webinar by registering online, with the opportunity to submit questions in advance and access a recording post-event.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.